Herriot Tabuteau

Herriot Tabuteau is the Founder, Chief Executive Officer, President, and Chairman of the Board at Axsome Therapeutics, having established and led the company since January 2012. " " "

He earned his M.D. from Yale University School of Medicine and a Bachelor's degree in molecular biology and biochemistry from Wesleyan University, laying a strong academic foundation for his career in healthcare and biotechnology. " "

Prior to founding Axsome, he held several influential roles in healthcare investment and research, contributing as a Senior Analyst, Partner, and investment banking professional at various firms. His early career helped shape the strategic vision that he brings to his leadership at Axsome Therapeutics. " " "

Stock Awards

Restricted Stock Units (RSUs)

• Grant Date: March 2, 2023. " "
• Number of Shares Granted: 62,400 RSUs. " "
• Grant Date Fair Value: $2,834,520. " "
• Vesting Schedule: Four equal annual installments over four years, fully vested on March 2, 2027 (with provisions for Change in Control, separation, or after seven years). " "
• Performance Metric: Based entirely on total shareholder return. "

Stock Options

• Grant Date: March 2, 2023. " "
• Number of Shares Granted: 110,032 stock options. " "
• Exercise Price: $65.32 per share. " "
• Grant Date Fair Value: $5,666,648. " "
• Vesting Schedule: 16 equal quarterly installments over four years, fully vested on March 2, 2027 with a ten-year term. " "
• Performance Metric: Value is driven by stock price appreciation. "

Non-Equity Incentive Plan Compensation

• Target Bonus: $450,000 (60% of base salary). " "
• Maximum Bonus: $900,000 (200% of target bonus). " "
• Actual Payout: $562,500 (125% of target bonus). "
• Performance Metrics & Weights:
  • Advance Our Pipeline: 30%. "
  • Drive Business Performance: 30%. "
  • Drive Business Expansion: 20%. "
  • Increase Awareness of Our Science, Business, and Products: 20%. "
• Evaluation Period & Conditions: Based on meeting operational performance goals including launching new target indications, completing development milestones, growing product sales, improving cash runway, securing licensing agreements, and expanding the field sales team. "